Cannabinoid signaling in health and disease

Canadian Journal of Physiology and Pharmacology

Volumn 95, Issue 4, 2017, Pages 311-327

  Lu, Yan ^a,b   Anderson, Hope D ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

2 arachidonoylglycerol; Anandamide; Cannabinoid receptor; Endocannabinoid; FAAH; MAGL

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; POLYUNSATURATED FATTY ACID; AMIDASE; ANALGESIC AGENT; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; MEDICAL CANNABIS;

ALZHEIMER DISEASE; APPETITE; ATHEROSCLEROSIS; CANNABIS USE; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DISEASES; ENERGY EXPENDITURE; HEALTH; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; LIPID DIET; MALIGNANT NEOPLASM; MITOCHONDRION; MOOD; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SLEEP; STRESS; VOMITING; AFFECT; ANIMAL; CANADA; CHEMISTRY; DRUG EFFECTS; FOOD INTAKE; METABOLISM; NEOPLASMS; NEURODEGENERATIVE DISEASES; PHYSIOLOGY;

AFFECT; AMIDOHYDROLASES; ANALGESICS; ANIMALS; APPETITE REGULATION; CANADA; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; CANNABIS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; HUMANS; MEDICAL MARIJUANA; MULTIPLE SCLEROSIS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PAIN; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; SLEEP; VOMITING;

EID: 85016456785     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2016-0346     Document Type: Review

References (259)

1. Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L.A., Pertwee, R.G., and Makriyannis, A. 1994. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37(12): 1889–1893. doi:10.1021/jm00038a020. PMID:8021930.
2. Agudo, J., Martin, M., Roca, C., Molas, M., Bura, A.S., Zimmer, A., et al. 2010. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia, 53(12): 2629– 2640. doi:10.1007/s00125-010-1894-6. PMID:20835701.
3. Ahmed, A., van der Marck, M.A., van den Elsen, G., and Olde Rikkert, M. 2015. Cannabinoids in late-onset Alzheimer’s disease. Clin. Pharmacol. Ther. 97(6): 597–606. doi:10.1002/cpt.117. PMID:25788394.
4. Alvheim, A.R., Malde, M.K., Osei-Hyiaman, D., Lin, Y.H., Pawlosky, R.J., Madsen, L., et al. 2012. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity (Silver Spring), 20(10): 1984–1994. doi:10.1038/oby.2012.38. PMID:22334255.
5. Annuzzi, G., Piscitelli, F., Di Marino, L., Patti, L., Giacco, R., Costabile, G., et al. 2010. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis. 9: 43. doi:10.1186/1476-511X-9-43. PMID:20426869.
6. Arrabal, S., Lucena, M.A., Canduela, M.J., Ramos-Uriarte, A., Rivera, P., Serrano, A., et al. 2015. Pharmacological blockade of cannabinoid CB1 receptors in diet-induced obesity regulates mitochondrial dihydrolipoamide dehydrogenase in muscle. PLoS One, 10(12): e0145244. doi:10.1371/journal.pone.0145244. PMID:26671069.
7. Artmann, A., Petersen, G., Hellgren, L.I., Boberg, J., Skonberg, C., Nellemann, C., et al. 2008. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim. Biophys. Acta, 1781(4): 200–212. doi:10.1016/j.bbalip.2008.01.006. PMID:18316044.
8. Aso, E., Palomer, E., Juves, S., Maldonado, R., Munoz, F.J., and Ferrer, I. 2012. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. J. Alzheimers Dis. 30(2): 439–459. doi:10.3233/JAD-2012-111862. PMID:22451318.
9. Athanasiou, A., Clarke, A.B., Turner, A.E., Kumaran, N.M., Vakilpour, S., Smith, P.A., et al. 2007. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem. Biophys. Res. Commun. 364(1): 131–137. doi:10.1016/j.bbrc.2007.09.107. PMID:17931597.
10. Bambico, F.R., Katz, N., Debonnel, G., and Gobbi, G. 2007. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 27(43): 11700–11711. doi:10.1523/JNEUROSCI.1636-07.2007. PMID:17959812.
11. Basavarajappa, B.S. 2007. Critical enzymes involved in endocannabinoid metabolism. Protein Pept. Lett. 14(3): 237–246. doi:10.2174/092986607780090829. PMID:17346227.
12. Battista, N., Fezza, F., Finazzi-Agro, A., and Maccarrone, M. 2006. The endocannabinoid system in neurodegeneration. Ital. J. Biochem. 55(3–4): 283–289. PMID:17274532.
13. Battista, N., Di Tommaso, M., Bari, M., and Maccarrone, M. 2012. The endocannabinoid system: an overview. Front. Behav. Neurosci. 6: 9. doi:10.3389/fnbeh.2012.00009. PMID:22457644.
14. Beal, J.E., Olson, R., Laubenstein, L., Morales, J.O., Bellman, P., Yangco, B., et al. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 10(2): 89–97. doi:10.1016/0885-3924(94)00117-4. PMID:7730690.
15. Becker, D.E. 2010. Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesth. Prog. 57(4): 150–156; quiz 157. doi:10.2344/0003-3006-57.4.150. PMID:21174569.
16. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., and Piomelli, D. 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277(5329): 1094–1097. doi:10.1126/science.277.5329.1094. PMID:9262477.
17. Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., and Reggiani, A. 2006. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23(6): 1530–1538. doi:10.1111/j.1460-9568.2006.04684.x. PMID:16553616.
18. Benard, G., Massa, F., Puente, N., Lourenco, J., Bellocchio, L., Soria-Gomez, E., et al. 2012. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat. Neurosci. 15(4): 558–564. doi:10.1038/nn.3053. PMID:22388959.
19. Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.H., Vogel, Z., et al. 1998. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353(1): 23–31. doi:10.1016/S0014-2999(98)00392-6. PMID:9721036.
20. Berge, K., Piscitelli, F., Hoem, N., Silvestri, C., Meyer, I., Banni, S., and Di Marzo, V. 2013. Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids Health Dis. 12: 78. doi:10.1186/1476-511X-12-78. PMID:23706001.
21. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., et al. 2010. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3): 764–774. doi:10.1038/npp.2009.184. PMID:19924114.
22. Bilfinger, T.V., Salzet, M., Fimiani, C., Deutsch, D.G., Tramu, G., and Stefano, G.B. 1998. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int. J. Cardiol. 64(Suppl. 1): S15–S22. doi:10.1016/S0167-5273(98)00031-X. PMID:9687088.
23. Bisogno, T., Berrendero, F., Ambrosino, G., Cebeira, M., Ramos, J.A., Fernandez-Ruiz, J.J., and Di Marzo, V. 1999. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res.Commun.256(2): 377–380. doi:10.1006/bbrc.1999.0254. PMID:10079192.
24. Blankman, J.L., Simon, G.M., and Cravatt, B.F. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14(12): 1347–1356. doi:10.1016/j.chembiol.2007.11.006. PMID:18096503.
25. Bonhaus, D.W., Chang, L.K., Kwan, J., and Martin, G.R. 1998. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287(3): 884–888. PMID:9864268.
26. Bonz, A., Laser, M., Kullmer, S., Kniesch, S., Babin-Ebell, J., Popp, V., et al. 2003. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. 41(4): 657–664. doi:10.1097/00005344-200304000-00020. PMID:12658069.
27. Bouchard, J.F., Lepicier, P., and Lamontagne, D. 2003. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci. 72(16): 1859–1870. doi:10.1016/S0024-3205(02)02474-8. PMID:12586223.
28. Brown, A.J., and Robin, Hiley, C. 2009. Is GPR55 an anandamide receptor? Vitam. Horm. 81: 111–137. doi:10.1016/S0083-6729(09)81005-4. PMID:19647110.
29. Brusco, A., Tagliaferro, P., Saez, T., and Onaivi, E.S. 2008. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse, 62(12): 944–949. doi:10.1002/syn.20569. PMID:18798269.
30. Cable, J.C., Tan, G.D., Alexander, S.P., and O’Sullivan, S.E. 2014. The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes. Lipids Health Dis. 13: 43. doi:10.1186/1476-511X-13-43. PMID:24593280.
31. Cadas, H., Gaillet, S., Beltramo, M., Venance, L., and Piomelli, D. 1996. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16(12): 3934–3942. PMID:8656287.
32. Cadas, H., di Tomaso, E., and Piomelli, D. 1997. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17(4): 1226–1242. PMID:9006968.
33. Caffarel, M.M., Andradas, C., Mira, E., Perez-Gomez, E., Cerutti, C., Moreno-Bueno, G., et al. 2010. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol. Cancer, 9: 196. doi:10.1186/1476-4598-9-196. PMID:20649976.
34. Callen, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortes, A., Mallol, J., et al. 2012. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol. Chem. 287(25): 20851–20865. doi:10.1074/jbc.M111.335273. PMID:22532560.
35. Carnevali, L., Vacondio, F., Rossi, S., Callegari, S., Macchi, E., Spadoni, G., et al. 2015. Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats. Eur. Neuropsychopharmacol. 25(11): 2157–2169. doi:10.1016/j.euroneuro.2015.07.015. PMID:26391492.
36. Carruba, M.O., Bondiolotti, G., Picotti, G.B., Catteruccia, N., and Da Prada, M. 1987. Effects of diethyl ether, halothane, ketamine and urethane on sympathetic activity in the rat. Eur. J. Pharmacol. 134(1): 15–24. doi:10.1016/0014-2999(87)90126-9. PMID:3556398.
37. Catanzaro, G., Rapino, C., Oddi, S., and Maccarrone, M. 2009. Anandamide increases swelling and reduces calcium sensitivity of mitochondria. Biochem. Biophys. Res. Commun. 388(2): 439–442. doi:10.1016/j.bbrc.2009.08.037. PMID: 19679102.
38. Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., and Astrup, A. 2007. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 370(9600): 1706–1713. doi:10.1016/S0140-6736(07)61721-8. PMID:18022033.
39. Chung, S.C., Hammarsten, P., Josefsson, A., Stattin, P., Granfors, T., Egevad, L., et al. 2009. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur. J. Cancer, 45(1): 174–182. doi:10.1016/j.ejca.2008.10.010. PMID:19056257.
40. Cianchi, F., Papucci, L., Schiavone, N., Lulli, M., Magnelli, L., Vinci, M.C., et al. 2008. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin. Cancer Res. 14(23): 7691–7700. doi:10.1158/1078-0432.CCR-08-0799. PMID:19047095.
41. Clapper, J.R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti, A., et al. 2010. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13(10): 1265–1270. doi:10.1038/nn.2632. PMID:20852626.
42. Cluny, N.L., Vemuri, V.K., Chambers, A.P., Limebeer, C.L., Bedard, H., Wood, J.T., et al. 2010. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br. J. Pharmacol. 161(3): 629–642. doi:10.1111/j.1476-5381.2010.00908.x. PMID:20880401.
43. Correa, F., Docagne, F., Mestre, L., Clemente, D., Hernangomez, M., Loria, F., and Guaza, C. 2009. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol. 77(1): 86–100. doi:10.1016/j.bcp.2008.09.014. PMID:18848818.
44. Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112(3): 423–431. doi:10.1172/JCI17725. PMID:12897210.
45. Cote, M., Matias, I., Lemieux, I., Petrosino, S., Almeras, N., Despres, J.P., and Di Marzo, V. 2007. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. (Lond.), 31(4): 692–699. doi:10.1038/sj.ijo.0803539. PMID:17224929.
46. Cravatt, B.F., and Lichtman, A.H. 2002. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem. Phys. Lipids, 121(1–2): 135–148. doi:10.1016/S0009-3084(02)00147-0. PMID:12505696.
47. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., et al. 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98(16): 9371–9376. doi:10.1073/pnas.161191698. PMID:11470906.
48. Curtis, A., Mitchell, I., Patel, S., Ives, N., and Rickards, H. 2009. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov. Disord. 24(15): 2254–2259. doi:10.1002/mds.22809. PMID:19845035.
49. Darmani, N.A. 2001. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol. Biochem. Behav. 69(1–2): 239–249. doi:10.1016/S0091-3057(01)00531-7. PMID:11420092.
50. de Lago, E., Moreno-Martet, M., Cabranes, A., Ramos, J.A., and Fernandez-Ruiz, J. 2012. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated antiinflammatory effects. Neuropharmacology, 62(7): 2299–2308. doi:10.1016/j.neuropharm.2012.01.030. PMID:22342378.
51. De Petrocellis, L, Melck, D, Palmisano, A, Bisogno, T, Laezza, C., Bifulco, M., and Di Marzo, V. 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 95(14): 8375– 8380. doi:10.1073/pnas.95.14.8375. PMID:9653194.
52. Demuth, D.G., and Molleman, A. 2006. Cannabinoid signalling. Life Sci. 78(6): 549–563. doi:10.1016/j.lfs.2005.05.055. PMID:16109430.
53. D’Eon, T.M., Pierce, K.A., Roix, J.J., Tyler, A., Chen, H., and Teixeira, S.R. 2008. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes, 57(5): 1262–1268. doi:10.2337/db07-1186. PMID:18276766.
54. Deutsch, D.G., and Chin, S.A. 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46(5): 791–796. doi:10.1016/0006-2952(93)90486-G. PMID:8373432.
55. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090): 1946–1949. doi:10.1126/science.1470919. PMID:1470919.
56. Di Marzo, V., and Despres, J.P. 2009. CB1 antagonists for obesity–what lessons have we learned from rimonabant? Nat. Rev. Endocrinol. 5(11): 633–638. doi:10.1038/nrendo.2009.197. PMID:19844251.
57. Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S., Jarai, Z., et al. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410(6830): 822–825. doi:10.1038/35071088. PMID:11298451.
58. Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., et al. 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 99(16): 10819–10824. doi:10.1073/pnas.152334899. PMID:12136125.
59. Dinh, T.P., Freund, T.F., and Piomelli, D. 2002. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids, 121(1–2): 149–158. doi:10.1016/S0009-3084(02)00150-0. PMID:12505697.
60. Duerr, G.D., Heinemann, J.C., Dunkel, S., Zimmer, A., Lutz, B., Lerner, R., et al. 2013. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci. 92(20–21): 976–983. doi:10.1016/j.lfs.2013.03.014. PMID:23567807.
61. Duran, M., Perez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., et al. 2010. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br. J. Clin. Pharmacol. 70(5): 656–663. doi:10.1111/j.1365-2125.2010.03743.x. PMID:21039759.
62. Dziadulewicz, E.K., Bevan, S.J., Brain, C.T., Coote, P.R., Culshaw, A.J., Davis, A.J., et al. 2007. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 50(16): 3851–3856. doi:10.1021/jm070317a. PMID:17630726.
63. El Manira, A., and Kyriakatos, A. 2010. The role of endocannabinoid signaling in motor control. Physiology (Bethesda), 25(4): 230–238. doi:10.1152/physiol.00007.2010. PMID:20699469.
64. Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P.M., Wolf, S., et al. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron, 49(1): 67–79. doi:10.1016/j.neuron.2005.11.027. PMID:16387640.
65. Engeli, S., Bohnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Batkai, S., et al. 2005. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 54(10): 2838–2843. doi:10.2337/diabetes.54.10.2838. PMID: 16186383.
66. Faure, L., Nagarajan, S., Hwang, H., Montgomery, C.L., Khan, B.R., John, G., et al. 2014. Synthesis of phenoxyacyl-ethanolamides and their effects on fatty acid amide hydrolase activity. J. Biol. Chem. 289(13): 9340–9351. doi:10.1074/jbc.M113.533315. PMID:24558037.
67. Felder, C.C., Joyce, K.E., Briley, E.M., Mansouri, J., Mackie, K., Blond, O., et al. 1995. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48(3): 443–450. PMID:7565624.
68. Felder, C.C., Nielsen, A., Briley, E.M., Palkovits, M., Priller, J., Axelrod, J., et al. 1996. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393(2–3): 231–235. doi:10.1016/0014-5793(96)00891-5. PMID:8814296.
69. Fernandes, E.S., Fernandes, M.A., and Keeble, J.E. 2012. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br. J. Pharmacol. 166(2): 510– 521. doi:10.1111/j.1476-5381.2012.01851.x. PMID:22233379.
70. Fimiani, C., Mattocks, D., Cavani, F., Salzet, M., Deutsch, D.G., Pryor, S., et al. 1999. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell. Signal. 11(3): 189–193. doi:10.1016/S0898-6568(98)00060-6. PMID:10353693.
71. Fisar, Z., Singh, N., and Hroudova, J. 2014. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicol. Lett. 231(1): 62–71. doi:10.1016/j.toxlet.2014.09.002. PMID:25195527.
72. Fitzgerald, K.T., Bronstein, A.C., and Newquist, K.L. 2013. Marijuana poisoning. Top. Companion Anim. Med. 28(1): 8–12. doi:10.1053/j.tcam.2013.03.004. PMID:23796481.
73. Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., et al. 2012. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci. 15(1): 64–69. doi:10.1038/nn.2986. PMID:22101642.
74. Galve-Roperh, I., Sanchez, C., Cortes, M.L., Gomez, del, Pulgar, T., Izquierdo, M., and Guzman, M. 2000. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6(3): 313–319. doi:10.1038/73171. PMID:10700234.
75. Garcia, C., Palomo-Garo, C., Garcia-Arencibia, M., Ramos, J., Pertwee, R., and Fernandez-Ruiz, J. 2011. Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol. 163(7): 1495–1506. doi:10.1111/j.1476-5381.2011.01278.x. PMID:21323909.
76. Garcia-Arencibia, M., Gonzalez, S., de Lago, E., Ramos, J.A., Mechoulam, R., and Fernandez-Ruiz, J. 2007. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134(1): 162–170. doi:10.1016/j.brainres.2006.11.063. PMID:17196181.
77. Gates, P.J., Albertella, L., and Copeland, J. 2014. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med. Rev. 18(6): 477–487. doi:10.1016/j.smrv.2014.02.005. PMID:24726015.
78. Gebremedhin, D., Lange, A.R., Campbell, W.B., Hillard, C.J., and Harder, D.R. 1999. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol. 276(6): H2085–H2093. PMID:10362691.
79. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.Z., Xie, X.Q., et al. 2008. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. U.S.A. 105(26): 9099–9104. doi:10.1073/pnas.0803601105. PMID:18574142.
80. Golech, S.A., McCarron, R.M., Chen, Y., Bembry, J., Lenz, F., Mechoulam, R., et al. 2004. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132(1): 87–92. doi:10.1016/j.molbrainres.2004.08.025. PMID:15548432.
81. Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, P.A., Brusco, A., and Uhl, G.R. 2006. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071(1): 10–23. doi:10.1016/j.brainres.2005.11.035. PMID:16472786.
82. Gonzalez, S., Scorticati, C., Garcia-Arencibia, M., de Miguel, R., Ramos, J.A., and Fernandez-Ruiz, J. 2006. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson’s disease. Brain Res. 1073– 1074: 209–219. doi:10.1016/j.brainres.2005.12.014. PMID:16412990.
83. Gorelick, D.A., Heishman, S.J., Preston, K.L., Nelson, R.A., Moolchan, E.T., and Huestis, M.A. 2006. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am. Heart J. 151(3): 754. e1-754.e5. doi:10.1016/j.ahj.2005.11.006. PMID:16504646.
84. Grant, I., Atkinson, J.H., Gouaux, B., and Wilsey, B. 2012. Medical marijuana: clearing away the smoke. Open Neurol. J. 6: 18–25. doi:10.2174/1874205X01206010018. PMID:22629287.
85. Grimaldi, C., Pisanti, S., Laezza, C., Malfitano, A.M., Santoro, A., Vitale, M., et al. 2006. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res. 312(4): 363–373. doi:10.1016/j.yexcr.2005.10.024. PMID:16343481.
86. Gui, H., Tong, Q., Qu, W., Mao, C.M., and Dai, S.M. 2015. The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. Int. Immunopharmacol. 26(1): 86–91. doi:10.1016/j.intimp.2015.03.006. PMID:25791728.
87. Gustafsson, S.B., Palmqvist, R., Henriksson, M.L., Dahlin, A.M., Edin, S., Jacobsson, S.O., et al. 2011. High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One, 6(8): e23003. doi:10.1371/journal.pone.0023003. PMID:21901119.
88. Harvey, B.S., Nicotra, L.L., Vu, M., and Smid, S.D. 2013. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine, 63(2): 209–217. doi:10.1016/j.cyto.2013.04.032. PMID:23706402.
89. Hashimotodani, Y., Ohno-Shosaku, T., Tanimura, A., Kita, Y., Sano, Y., Shimizu, T., et al. 2013. Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling: evidence for on-demand biosynthesis of 2-arachidonoylglycerol. J. Physiol. 591(19): 4765–4776. doi:10.1113/jphysiol.2013.254474. PMID:23858009.
90. Heinbockel, T., Brager, D.H., Reich, C.G., Zhao, J., Muralidharan, S., Alger, B.E., and Kao, J.P. 2005. Endocannabinoid signaling dynamics probed with optical tools. J. Neurosci. 25(41): 9449–9459. doi:10.1523/JNEUROSCI.2078-05.2005. PMID:16221855.
91. Henstridge, C.M., Balenga, N.A., Ford, L.A., Ross, R.A., Waldhoer, M., and Irving, A.J. 2009. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. 23(1): 183–193. doi:10.1096/fj.08-108670. PMID:18757503.
92. Hernandez-Torres, G., Cipriano, M., Heden, E., Bjorklund, E., Canales, A., Zian, D., et al. 2014. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew. Chem. Int. Ed. Engl. 53(50): 13765–13770. doi:10.1002/anie.201407807. PMID:25298214.
93. Hill, M.N., Miller, G.E., Ho, W.S., Gorzalka, B.B., and Hillard, C.J. 2008. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry, 41(2): 48–53. doi:10.1055/s-2007-993211. PMID:18311684.
94. Hillard, C.J., Manna, S., Greenberg, M.J., DiCamelli, R., Ross, R.A., Stevenson, L.A., et al. 1999. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289(3): 1427–1433. PMID:10336536.
95. Ho, W.S., and Randall, M.D. 2007. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br. J. Pharmacol. 150(5): 641–651. doi:10.1038/sj.bjp.0707141. PMID:17245358.
96. Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., et al. 2005. An endocannabinoid mechanism for stress-induced analgesia. Nature, 435(7045): 1108–1112. doi:10.1038/nature03658. PMID:15973410.
97. Horvath, B., Mukhopadhyay, P., Hasko, G., and Pacher, P. 2012. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am. J. Pathol. 180(2): 432–442. doi:10.1016/j.ajpath.2011.11.003. PMID:22155112.
98. Hosking, R.D., and Zajicek, J.P. 2008. Therapeutic potential of cannabis in pain medicine. Br. J. Anaesth. 101(1): 59–68. doi:10.1093/bja/aen119. PMID: 18515270.
99. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W. A, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54(2): 161–202. doi:10.1124/pr.54.2.161. PMID: 12037135.
100. Hsiao, W.C., Shia, K.S., Wang, Y.T., Yeh, Y.N., Chang, C.P., Lin, Y., et al. 2015. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Diabetes Obes. Metab. 17(5): 495–504. doi:10.1111/dom.12447. PMID:25656402.
101. Hu, D.L., Zhu, G., Mori, F., Omoe, K., Okada, M., Wakabayashi, K., et al. 2007. Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Cell. Microbiol. 9(9): 2267–2277. doi:10.1111/j.1462-5822.2007.00957.x. PMID:17517065.
102. Huang, W., Rubinstein, J., Prieto, A.R., Thang, L.V., and Wang, D.H. 2009. Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension, 53(2): 243–250. doi:10.1161/HYPERTENSIONAHA.108.118349. PMID:19114647.
103. Huestis, M.A., Boyd, S.J., Heishman, S.J., Preston, K.L., Bonnet, D., Le Fur, G., and Gorelick, D.A. 2007. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl.), 194(4): 505–515. doi:10.1007/s00213-007-0861-5. PMID:17619859.
104. Huffman, J.W., Liddle, J., Yu, S., Aung, M.M., Abood, M.E., Wiley, J.L., and Martin, B.R. 1999. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 7(12): 2905–2914. doi:10.1016/S0968-0896(99)00219-9. PMID:10658595.
105. Ibrahim, M.M., Deng, H., Zvonok, A., Cockayne, D.A., Kwan, J., Mata, H.P., et al. 2003. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U.S.A. 100(18): 10529–10533. doi:10.1073/pnas.1834309100. PMID:12917492.
106. Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes, E., Peleraux, A., et al. 2005. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19(11): 1567–1569. doi:10.1096/fj.04-3177fje. PMID:16009704.
107. Jiang, L.S., Pu, J., Han, Z.H., Hu, L.H., and He, B. 2009. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc. Res. 81(4): 805–813. doi:10.1093/cvr/cvn344. PMID:19074161.
108. Jung, M., Calassi, R., Rinaldi-Carmona, M., Chardenot, P., Le Fur, G., Soubrie, P., and Oury-Donat, F. 1997. Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. J. Neurochem. 68(1): 402–409. doi:10.1046/j.1471-4159.1997.68010402.x. PMID:8978752.
109. Kalant, H., and Porath-Waller, A.J. 2012. Clearing the smoke on cannabis: medical use of cannabis and cannabinoids. Canadian Centre on Substance Abuse. Canadian Electronic Library. Available from http://www.ccsa.ca/Resource%20Library/CCSA-Medical-Use-of-Cannabis-Report-2016-en.pdf.
110. Karlsson, M., Contreras, J.A., Hellman, U., Tornqvist, H., and Holm, C. 1997. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J. Biol. Chem. 272(43): 27218–27223. doi:10.1074/jbc.272.43.27218. PMID:9341166.
111. Karschner, E.L., Darwin, W.D., McMahon, R.P., Liu, F., Wright, S., Goodwin, R.S., and Huestis, M.A. 2011. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin. Pharmacol. Ther. 89(3): 400–407. doi:10.1038/clpt.2010.318. PMID:21289620.
112. Katayama, K., Ueda, N., Katoh, I., and Yamamoto, S. 1999. Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim. Biophys. Acta, 1440(2–3): 205–214. doi:10.1016/S1388-1981(99)00124-9. PMID:10521704.
113. Kelsey, J.E., Harris, O., and Cassin, J. 2009. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson’s disease. Behav. Brain Res. 203(2): 304–307. doi:10.1016/j.bbr.2009.04.035. PMID:19414037.
114. Khanolkar, A.D., Abadji, V., Lin, S., Hill, W.A., Taha, G., Abouzid, K., et al. 1996. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39(22): 4515–4519. doi:10.1021/jm960152y. PMID: 8893848.
115. Kim, J., and Li, Y. 2015. Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission. J. Physiol. 593(4): 871–886. doi:10.1113/jphysiol.2014.286633. PMID:25504573.
116. Kirkham, T.C., Williams, C.M., Fezza, F., and Di Marzo, V. 2002. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136(4): 550–557. doi:10.1038/sj.bjp.0704767. PMID:12055133.
117. Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., and Sugiura, T. 1998. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett. 429(2): 152–156. doi:10.1016/S0014-5793(98)00581-X. PMID:9650580.
118. Krishnan, G., and Chatterjee, N. 2012. Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. Glia, 60(11): 1629–1645. doi:10.1002/glia.22380. PMID: 22807196.
119. Kunos, G., Osei-Hyiaman, D., Batkai, S., Sharkey, K.A., and Makriyannis, A. 2009. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol. Sci. 30(1): 1–7. doi:10.1016/j.tips.2008.10.001. PMID:19042036.
120. Kurz, C., Baranowska, U., Lupinski, S., Gothert, M., Malinowska, B., and Schlicker, E. 2009. Urethane, but not pentobarbitone, attenuates presynaptic receptor function in rats: a contribution to the choice of anaesthetic. Br. J. Pharmacol. 157(8): 1474–1482. doi:10.1111/j.1476-5381.2009.00315.x. PMID:19681871.
121. Laezza, C., Pisanti, S., Malfitano, A.M., and Bifulco, M. 2008. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr. Relat. Cancer, 15(4): 965–974. doi:10.1677/ERC-08-0030. PMID:18676619.
122. Lagneux, C., and Lamontagne, D. 2001. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol. 132(4): 793–796. doi:10.1038/sj.bjp.0703902. PMID:11181418.
123. Lake, K.D., Compton, D.R., Varga, K., Martin, B.R., and Kunos, G. 1997a. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 281(3): 1030–1037. PMID: 9190833.
124. Lake, K.D., Martin, B.R., Kunos, G., and Varga, K. 1997b. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension, 29(5): 1204–1210. doi:10.1161/01.HYP.29.5.1204. PMID: 9149688.
125. Lan, R., Gatley, J., Lu, Q., Fan, P., Fernando, S.R., Volkow, N.D., et al. 1999a. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci. 1(2): E4. doi:10.1208/ps010204. PMID: 11741201.
126. Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S.R., McCallion, D., et al. 1999b. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42(4): 769–776. doi:10.1021/jm980363y. PMID: 10052983.
127. Laprairie, R.B., Kelly, M.E., and Denovan-Wright, E.M. 2013. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington’s disease. Neuropharmacology, 72: 47–57. doi:10.1016/j.neuropharm.2013.04.006. PMID:23602984.
128. Lastres-Becker, I., Fezza, F., Cebeira, M., Bisogno, T., Ramos, J.A., Milone, A., et al. 2001. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease. Neuroreport, 12(10): 2125–2129. doi:10.1097/00001756-200107200-00017. PMID:11447320.
129. Latini, L., Bisicchia, E., Sasso, V., Chiurchiu, V., Cavallucci, V., Molinari, M., et al. 2014. Cannabinoid CB2 receptor (CB2R) stimulation delays rubrospinal mitochondrial-dependent degeneration and improves functional recovery after spinal cord hemisection by ERK1/2 inactivation. Cell Death Dis. 5: e1404. doi:10.1038/cddis.2014.364. PMID:25188514.
130. Lauckner, J.E., Hille, B., and Mackie, K. 2005. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. U.S.A. 102(52): 19144–19149. doi:10.1073/pnas.0509588102. PMID:16365309.
131. Lepicier, P., Bouchard, J.F., Lagneux, C., and Lamontagne, D. 2003. Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol. 139(4): 805–815. doi:10.1038/sj.bjp.0705313. PMID:12813004.
132. Li, C., Jones, P.M., and Persaud, S.J. 2011. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol. Ther. 129(3): 307–320. doi:10.1016/j.pharmthera.2010.10.006. PMID:21055418.
133. Li, Q., Shi, M., and Li, B. 2013a. Anandamide enhances expression of heat shock protein 72 to protect against ischemia-reperfusion injury in rat heart. J. Physiol. Sci. 63(1): 47–53. doi:10.1007/s12576-012-0228-5. PMID:23007622.
134. Li, Q., Wang, F., Zhang, Y.M., Zhou, J.J., and Zhang, Y. 2013b. Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis. Cell. Physiol. Biochem. 31(4–5): 693–702. doi:10.1159/000350088. PMID:23711495.
135. Li, Q., Guo, H.C., Maslov, L.N., Qiao, X.W., Zhou, J.J., and Zhang, Y. 2014. Mitochondrial permeability transition pore plays a role in the cardioprotection of CB2 receptor against ischemia-reperfusion injury. Can. J. Physiol. Pharmacol. 92(3): 205–214. doi:10.1139/cjpp-2013-0293. PMID:24593785.
136. Liao, Y., Bin, J., Asakura, M., Xuan, W., Chen, B., Huang, Q., et al. 2012. Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. Eur. Heart J. 33(24): 3124–3133. doi:10.1093/eurheartj/ehr246. PMID:21785110.
137. Liao, Y., Bin, J., Luo, T., Zhao, H., Ledent, C., Asakura, M., et al. 2013. CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice. Int. J. Cardiol. 167(5): 1936–1944. doi:10.1016/j.ijcard.2012.05.033. PMID:22656047.
138. Lile, J.A., Kelly, T.H., and Hays, L.R. 2011. Separate and combined effects of the cannabinoid agonists nabilone and Delta(9)-THC in humans discriminating Delta(9)-THC. Drug Alcohol Depend. 116(1–3): 86–92. doi:10.1016/j.drugalcdep.2010.11.019. PMID:21227600.
139. Lin, C.Y., Hsu, Y.J., Hsu, S.C., Chen, Y., Lee, H.S., Lin, S.H., et al. 2015. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Aktmediated cardiac fibrosis in experimental uremia. J. Mol. Cell. Cardiol. 85: 249–261. doi:10.1016/j.yjmcc.2015.06.010. PMID:26093151.
140. Liu, J., Gao, B., Mirshahi, F., Sanyal, A.J., Khanolkar, A.D., Makriyannis, A., and Kunos, G. 2000. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346(3): 835–840. doi:10.1042/bj3460835. PMID: 10698714.
141. Lodola, A., Castelli, R., Mor, M., and Rivara, S. 2015. Fatty acid amide hydrolase inhibitors: a patent review (2009-2014). Expert Opin. Ther. Pat. 25(11): 1247– 1266. doi:10.1517/13543776.2015.1067683. PMID:26413912.
142. Lu, Y., Akinwumi, B.C., Shao, Z., and Anderson, H.D. 2014. Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes. J. Cardiovasc. Pharmacol. 64(5): 420–430. doi:10.1097/FJC.0000000000000134. PMID:24979612.
143. Maccarrone, M., van der Stelt, M., Rossi, A., Veldink, G.A., Vliegenthart, J.F., and Agro, A.F. 1998. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273(48): 32332–32339. doi:10.1074/jbc.273.48.32332. PMID: 9822713.
144. Mackie, K., Devane, W.A., and Hille, B. 1993. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44(3): 498–503. PMID:8371711.
145. Malan, T.P., Jr, Ibrahim, M.M., Lai, J., Vanderah, T.W., Makriyannis, A., and Porreca, F. 2003. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. 3(1): 62–67. doi:10.1016/S1471-4892(02)00004-8. PMID:12550743.
146. Malinowska, B., Kwolek, G., and Gothert, M. 2001. Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn SchmiedebergsArch.Pharmacol.364(6):562–569.doi:10.1007/s00210-001-0498-6. PMID:11770012.
147. Manuel, I., Gonzalez de San Roman, E., Giralt, M.T., Ferrer, I., and Rodriguez-Puertas, R. 2014. Type-1 cannabinoid receptor activity during Alzheimer’s disease progression. J. Alzheimers Dis.42(3): 761–766. doi:10.3233/JAD-140492. PMID:24946872.
148. Marco, E.M., Echeverry-Alzate, V., Lopez-Moreno, J.A., Gine, E., Penasco, S., and Viveros, M.P. 2014. Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. Behav. Pharmacol. 25(5–6): 547–556. doi:10.1097/FBP.0000000000000068. PMID:25083571.
149. Marriott, K.S., and Huffman, J.W. 2008. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem. 8(3): 187–204. doi:10.2174/156802608783498014. PMID:18289088.
150. Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G., et al. 2002. The endogenous cannabinoid system controls extinction of aversive memories. Nature, 418(6897): 530–534. doi:10.1038/nature00839. PMID: 12152079.
151. Mastinu, A., Pira, M., Pani, L., Pinna, G.A., and Lazzari, P. 2012. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behav. Brain Res. 234(2): 192–204. doi:10.1016/j.bbr.2012.06.033. PMID:22771813.
152. Mathew, R.J., Wilson, W.H., and Davis, R. 2003. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol. Biochem. Behav. 75(2): 309–318. doi:10.1016/S0091-3057(03)00086-8. PMID: 12873621.
153. Matias, I., Gonthier, M.P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., et al. 2006. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab.91(8): 3171–3180. doi:10.1210/jc.2005-2679. PMID:16684820.
154. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284): 561–564. doi:10.1038/346561a0. PMID:2165569.
155. Mazzola, C., Micale, V., and Drago, F. 2003. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477(3): 219–225. doi:10.1016/j.ejphar.2003.08.026. PMID:14522360.
156. McAllister, S.D., and Glass, M. 2002. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids, 66(2–3): 161–171. doi:10.1054/plef.2001.0344. PMID:12052033.
157. McDougle, D.R., Kambalyal, A., Meling, D.D., and Das, A. 2014. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. J. Pharmacol. Exp. Ther. 351(3): 616–627. doi:10.1124/jpet.114.216598. PMID:25277139.
158. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50(1): 83–90. doi:10.1016/0006-2952(95)00109-D. PMID:7605349.
159. Mechoulam, R., Fride, E., Ben-Shabat, S., Meiri, U., and Horowitz, M. 1998a. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur. J. Pharmacol. 362(1): R1–R3. doi:10.1016/S0014-2999(98)00777-8. PMID:9865537.
160. Mechoulam, R., Fride, E., and Di Marzo, V. 1998b. Endocannabinoids. Eur. J. Pharmacol. 359(1): 1–18. doi:10.1016/S0014-2999(98)00649-9. PMID:9831287.
161. Meiri, E., Jhangiani, H., Vredenburgh, J.J., Barbato, L.M., Carter, F.J., Yang, H.M., et al. 2007. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin. 23(3): 533–543. doi:10.1185/030079907X167525. PMID:17355735.
162. Mendez-Diaz, M., Caynas-Rojas, S., Arteaga Santacruz, V., Ruiz-Contreras, A.E., Aguilar-Roblero, R., and Prospero-Garcia, O. 2013. Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats. Pharmacol. Biochem. Behav. 107: 29–35. doi:10.1016/j.pbb.2013.04.003. PMID: 23584096.
163. Mombouli, J.V., Schaeffer, G., Holzmann, S., Kostner, G.M., and Graier, W.F. 1999. Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Br. J. Pharmacol. 126(7): 1593–1600. doi:10.1038/sj.bjp.0702483. PMID: 10323591.
164. Moreira, F.A., Aguiar, D.C., and Guimaraes, F.S. 2007. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology, 52(3): 958–965. doi:10.1016/j.neuropharm.2006.10.013. PMID: 17156799.
165. Moreira, F.A., Grieb, M., and Lutz, B. 2009. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 23(1): 133–144. doi:10.1016/j.beem.2008.09.003. PMID:19285266.
166. Morena, M., De Castro, V., Gray, J.M., Palmery, M., Trezza, V., Roozendaal, B., et al. 2015. Training-associated emotional arousal shapes endocannabinoid modulation of spatial memory retrieval in rats. J. Neurosci. 35(41): 13962– 13974. doi:10.1523/JNEUROSCI.1983-15.2015. PMID:26468197.
167. Mukhopadhyay, P., Batkai, S., Rajesh, M., Czifra, N., Harvey-White, J., Hasko, G., et al. 2007. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50(6): 528– 536. doi:10.1016/j.jacc.2007.03.057. PMID:17678736.
168. Munro, S., Thomas, K.L., and Abu-Shaar, M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441): 61–65. doi:10.1038/365061a0. PMID:7689702.
169. Murillo-Rodriguez, E., Blanco-Centurion, C., Sanchez, C., Piomelli, D., and Shiromani, P.J. 2003. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep, 26(8): 943–947. PMID:14746372.
170. Murillo-Rodriguez, E., Millan-Aldaco, D., Di Marzo, V., and Drucker-Colin, R. 2008. The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience, 157(1): 1–11. doi:10.1016/j.neuroscience.2008.08.056. PMID:18822353.
171. Nathan, P.J., O’Neill, B.V., Napolitano, A., and Bullmore, E.T. 2011. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci. Ther. 17(5): 490–505. doi:10.1111/j.1755-5949.2010.00172.x. PMID:21951371.
172. Niederhoffer, N., Hansen, H.H., Fernandez-Ruiz, J.J., and Szabo, B. 2001. Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br. J. Pharmacol. 134(6): 1319–1327. doi:10.1038/sj.bjp.0704359. PMID:11704653.
173. Nishida, M., Tanabe, S., Maruyama, Y., Mangmool, S., Urayama, K., Nagamatsu, Y., et al. 2005. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2- terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J. Biol. Chem. 280(18): 18434–18441. doi:10.1074/jbc.M409710200. PMID:15743761.
174. Nissen, S.E., Nicholls, S.J., Wolski, K., Rodes-Cabau, J., Cannon, C.P., Deanfield, J.E., et al.; STRADIVARIUS Investigators. 2008. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA, 299(13): 1547–1560. doi:10.1001/jama.299.13.1547. PMID:18387931.
175. Nithipatikom, K., Gomez-Granados, A.D., Tang, A.T., Pfeiffer, A.W., Williams, C.L., and Campbell, W.B. 2012. Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. Endocrinology, 153(1): 29–41. doi:10.1210/en.2011-1144. PMID:22087025.
176. O’Brien, L.D., Limebeer, C.L., Rock, E.M., Bottegoni, G., Piomelli, D., and Parker, L.A. 2013. Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus). Br. J. Pharmacol. 170(5): 1130–1136. doi:10.1111/bph.12360. PMID:23991698.
177. O’Leary, D.H., Reuwer, A.Q., Nissen, S.E., Despres, J.P., Deanfield, J.E., Brown, M.W., et al. 2011. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart, 97(14): 1143–1150. doi:10.1136/hrt.2011.223446. PMID:21610270.
178. Onaivi, E.S., Carpio, O., Ishiguro, H., Schanz, N., Uhl, G.R., and Benno, R. 2008. Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann. N.Y. Acad. Sci. 1139: 426–433. doi:10.1196/annals.1432.035. PMID:18991890.
179. Orellana-Serradell, O., Poblete, C.E., Sanchez, C., Castellon, E.A., Gallegos, I., Huidobro, C., et al. 2015. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol. Rep. 33(4): 1599–1608. doi:10.3892/or.2015.3746. PMID: 25606819.
180. Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Batkai, S., et al. 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115(5): 1298–1305. doi:10.1172/JCI200523057. PMID:15864349.
181. Pacher, P., Batkai, S., and Kunos, G. 2004. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J. Physiol. 558(2): 647–657. doi:10.1113/jphysiol.2004.064824. PMID:15121805.
182. Pacher, P., Batkai, S., and Kunos, G. 2006. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58(3): 389–462. doi:10.1124/pr.58.3.2. PMID:16968947.
183. Palazuelos, J., Aguado, T., Egia, A., Mechoulam, R., Guzman, M., and Galve-Roperh, I. 2006. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 20(13): 2405–2407. doi:10.1096/fj.06-6164fje. PMID:17015409.
184. Pava, M.J., den Hartog, C.R., Blanco-Centurion, C., Shiromani, P.J., and Woodward, J.J. 2014. Endocannabinoid modulation of cortical up-states and NREM sleep. PLoS One, 9(2): e88672. doi:10.1371/journal.pone.0088672. PMID: 24520411.
185. Pava, M.J., Makriyannis, A., and Lovinger, D.M. 2016. Endocannabinoid signaling regulates sleep stability. PLoS One, 11(3): e0152473. doi:10.1371/journal.pone.0152473. PMID:27031992.
186. Pertwee, R.G. 1999. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6(8): 635–664. PMID:10469884.
187. Pertwee, R.G. 2006. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. (Lond.), 30(Suppl. 1): S13–S18. doi:10.1038/sj.ijo.0803272. PMID:16570099.
188. Pertwee, R.G. 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br. J. Pharmacol. 153(2): 199–215. doi:10.1038/sj.bjp.0707442. PMID:17828291.
189. Pertwee, R.G. 2014. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc. Nutr. Soc. 73(1): 96–105. doi:10.1017/S0029665113003649. PMID:24135210.
190. Piomelli, D. 2003. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4(11): 873–884. doi:10.1038/nrn1247. PMID:14595399.
191. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., and RIONorth America Study Group. 2006. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 295(7): 761–775. doi:10.1001/jama.295.7.761. PMID:16478899.
192. Preet, A., Ganju, R.K., and Groopman, J.E. 2008. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene, 27(3): 339–346. doi:10.1038/sj.onc.1210641. PMID:17621270.
193. Price, D.A., Martinez, A.A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., et al. 2009. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur. J. Neurosci. 29(11): 2177–2186. doi:10.1111/j.1460-9568.2009.06764.x. PMID:19490092.
194. Quarta, C., Bellocchio, L., Mancini, G., Mazza, R., Cervino, C., Braulke, L.J., et al. 2010. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 11(4): 273–285. doi:10.1016/j.cmet.2010.02.015. PMID:20374960.
195. Rajesh, M., Mukhopadhyay, P., Hasko, G., Huffman, J.W., Mackie, K., and Pacher, P. 2008a. CB2 cannabinoid receptor agonists attenuate TNF-alphainduced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. 153(2): 347–357. doi:10.1038/sj.bjp.0707569. PMID:17994109.
196. Rajesh, M., Mukhopadhyay, P., Hasko, G., and Pacher, P. 2008b. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem. Biophys. Res. Commun. 377(4): 1248–1252. doi:10.1016/j.bbrc.2008.10.159. PMID:18996082.
197. Rakhshandehroo, M., Sanderson, L.M., Matilainen, M., Stienstra, R., Carlberg, C., de Groot, P.J., et al. 2007. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res. 2007: 26839. doi:10.1155/2007/26839. PMID:18288265.
198. Ramer, R., Merkord, J., Rohde, H., and Hinz, B. 2010. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 79(7): 955–966. doi:10.1016/j.bcp.2009.11.007. PMID:19914218.
199. Ramirez, B.G., Blazquez, C., Gomez, del, Pulgar, T., Guzman, M., and de Ceballos, M.L. 2005. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25(8): 1904–1913. doi:10.1523/JNEUROSCI.4540-04.2005. PMID:15728830.
200. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Alonso, R., Shire, D., Congy, C., et al. 1995. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56(23–24): 1941–1947. doi:10.1016/0024-3205(95)00174-5. PMID:7776817.
201. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.M., Casellas, P., Congy, C., et al. 1998. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284(2): 644–650. PMID: 9454810.
202. Romero, T.R.L., Resende, L.C., Guzzo, L.S., and Duarte, I.D.G. 2013. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth. Analg. 116(2): 463–472. doi:10.1213/ANE.0b013e3182707859. PMID:23302980.
203. Ross, R.A. 2003. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol 140(5): 790–801. doi:10.1038/sj.bjp.0705467. PMID:14517174.
204. Ross, R.A., Brockie, H.C., Stevenson, L.A., Murphy, V.L., Templeton, F., Makriyannis, A., and Pertwee, R.G. 1999. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 126(3): 665–672. doi:10.1038/sj.bjp.0702351. PMID: 10188977.
205. Rouzer, C.A., and Marnett, L.J. 2011. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev. 111(10): 5899–5921. doi:10.1021/cr2002799. PMID:21923193.
206. Rubino, T., Guidali, C., Vigano, D., Realini, N., Valenti, M., Massi, P., and Parolaro, D. 2008. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology, 54(1): 151–160. doi:10.1016/j.neuropharm.2007.06.024. PMID:17692344.
207. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N.O., Leonova, J., et al. 2007. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152(7): 1092–1101. doi:10.1038/sj.bjp.0707460. PMID:17876302.
208. Saario, S.M., Savinainen, J.R., Laitinen, J.T., Jarvinen, T., and Niemi, R. 2004. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 67(7): 1381–1387. doi:10.1016/j.bcp.2003.12.003. PMID:15013854.
209. Sagredo, O., Gonzalez, S., Aroyo, I., Pazos, M.R., Benito, C., Lastres-Becker, I., et al. 2009. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease. Glia, 57(11): 1154–1167. doi:10.1002/glia.20838. PMID:19115380.
210. Sanchez, C., de Ceballos, M.L., Gomez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G., et al. 2001. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61(15): 5784–5789. PMID:11479216.
211. Sanchez Lopez, A.J., Roman-Vega, L., Ramil Tojeiro, E., Giuffrida, A., and Garcia-Merino, A. 2015. Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-beta: a longitudinal study in multiple sclerosis patients. Clin. Exp. Immunol. 179(1): 119–127. doi:10.1111/cei.12443. PMID:25169051.
212. Santucci, V., Storme, J.J., Soubrie, P., and Le Fur, G. 1996. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci. 58(6): PL103–PL110. doi:10.1016/0024-3205(95)02319-4. PMID: 8569415.
213. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F., and RIODiabetes Study Group. 2006. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet, 368(9548): 1660–1672. doi:10.1016/S0140-6736(06)69571-8. PMID:17098084.
214. Schmid, P.C., Krebsbach, R.J., Perry, S.R., Dettmer, T.M., Maasson, J.L., and Schmid, H.H. 1995. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375(1–2): 117–120. doi:10.1016/0014-5793(95)01194-J. PMID:7498458.
215. Senogles, S.E. 2000. The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine. Mol. Pharmacol. 58(2): 455–462. doi:10.1124/mol.58.2.455. PMID:10908315.
216. Sharkey, K.A., Darmani, N.A., and Parker, L.A. 2014. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur. J. Pharmacol. 722: 134–146. doi:10.1016/j.ejphar.2013.09.068. PMID:24184696.
217. Shen, M., and Thayer, S.A. 1998. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783(1): 77–84. doi:10.1016/S0006-8993(97)01195-5. PMID:9479052.
218. Showalter, V.M., Compton, D.R., Martin, B.R., and Abood, M.E. 1996. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278(3): 989–999. PMID:8819477.
219. Siegmund, S.V., Qian, T., de Minicis, S., Harvey-White, J., Kunos, G., Vinod, K.Y., et al. 2007. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J. 21(11): 2798–2806. doi:10.1096/fj.06-7717com. PMID:17440119.
220. Skaper, S.D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., and Leon, A. 1996. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U.S.A. 93(9): 3984–3989. doi:10.1073/pnas.93.9.3984. PMID:8633002.
221. Steffens, S., Veillard, N.R., Arnaud, C., Pelli, G., Burger, F., Staub, C., et al. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 434(7034): 782–786. doi:10.1038/nature03389. PMID:15815632.
222. Stella, N., and Piomelli, D. 2001. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425(3): 189–196. doi:10.1016/S0014-2999(01)01182-7. PMID:11513837.
223. Stella, N., Schweitzer, P., and Piomelli, D. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388(6644): 773–778. doi:10.1038/42015. PMID:9285589.
224. Storr, M., Keenan, C., Zhang, H., Patel, K., Makriyannis, A., and Sharkey, K. 2009. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm. Bowel Dis. 15(11): 1678–1685. doi:10.1002/ibd.20960. PMID: 19408320.
225. Sugamura, K., Sugiyama, S., Fujiwara, Y., Matsubara, J., Akiyama, E., Maeda, H., et al. 2010. Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport. J. Atheroscler. Thromb. 17(2): 141– 147. doi:10.5551/jat.2865. PMID:20124735.
226. Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Yamashita, A., et al. 1996. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240(1): 53–62. doi:10.1111/j.1432-1033.1996.0053h.x. PMID:8797835.
227. Szaflarski, J.P., and Bebin, E.M. 2014. Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy Behav. 41: 277–282. doi:10.1016/j.yebeh.2014.08.135. PMID:25282526.
228. Tam, J., Vemuri, V.K., Liu, J., Batkai, S., Mukhopadhyay, B., Godlewski, G., et al. 2010. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 120(8): 2953–2966. doi:10.1172/JCI42551. PMID:20664173.
229. Tedesco, L., Valerio, A., Dossena, M., Cardile, A., Ragni, M., Pagano, C., et al. 2010. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes, 59(11): 2826–2836. doi:10.2337/db09-1881. PMID:20739683.
230. Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., and Pertwee, R.G. 2007. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150(5): 613–623. doi:10.1038/sj.bjp.0707133. PMID:17245363.
231. Torres, S., Lorente, M., Rodriguez-Fornes, F., Hernandez-Tiedra, S., Salazar, M., Garcia-Taboada, E., et al. 2011. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10(1): 90–103. doi:10.1158/1535-7163.MCT-10-0688. PMID:21220494.
232. Toth, A., Blumberg, P.M., and Boczan, J. 2009. Anandamide and the vanilloid receptor (TRPV1). Vitam. Horm. 81: 389–419. doi:10.1016/S0083-6729(09)81015-7. PMID:19647120.
233. Tourino, C., Oveisi, F., Lockney, J., Piomelli, D., and Maldonado, R. 2010. FAAH deficiency promotes energy storage and enhances the motivation for food. Int. J. Obes. (Lond.), 34(3): 557–568. doi:10.1038/ijo.2009.262. PMID:20029375.
234. Ueda, N., Yamanaka, K., and Yamamoto, S. 2001. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276(38): 35552–35557. doi:10.1074/jbc.M106261200. PMID:11463796.
235. Valdeolivas, S., Satta, V., Pertwee, R.G., Fernandez-Ruiz, J., and Sagredo, O. 2012. Sativex-like combination of phytocannabinoids is neuroprotective in malonatelesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem. Neurosci. 3(5): 400–406. doi:10.1021/cn200114w. PMID:22860209.
236. Valk, P.J., and Delwel, R. 1998. The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Leuk. Lymphoma, 32(1–2): 29–43. doi:10.3109/10428199809059244. PMID: 10036999.
237. Van Der Stelt, M., and Di Marzo, V. 2004. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur. J. Biochem. 271(10): 1827–1834. doi:10.1111/j.1432-1033.2004.04081.x. PMID:15128293.
238. Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., Rossner, S., and RIOEurope Study Group. 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365(9468): 1389–1397. doi:10.1016/S0140-6736(05)66374-X. PMID:15836887.
239. Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., et al. 2005. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310(5746): 329–332. doi:10.1126/science.1115740. PMID:16224028.
240. Verty, A.N., Allen, A.M., and Oldfield, B.J. 2009. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring), 17(2): 254–261. doi:10.1038/oby.2008.509. PMID:19057531.
241. Verty, A.N., Stefanidis, A., McAinch, A.J., Hryciw, D.H., and Oldfield, B. 2015. Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLoS One, 10(11): e0140592. doi:10.1371/journal.pone.0140592. PMID: 26588700.
242. Vijayakumar, R.S., Lin, Y., Shia, K.S., Yeh, Y.N., Hsieh, W.P., Hsiao, W.C., et al. 2012. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors. Int. J. Obes. (Lond.), 36(7): 999–1006. doi:10.1038/ijo.2011.171. PMID:21894162.
243. Viveros, M.P., Marco, E.M., and File, S.E. 2005. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 81(2): 331–342. doi:10.1016/j.pbb.2005.01.029. PMID:15927244.
244. Wagner, J.A., Hu, K., Karcher, J., Bauersachs, J., Schafer, A., Laser, M., et al. 2003. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br. J. Pharmacol. 138(7): 1251–1258. doi:10.1038/sj.bjp.0705156. PMID:12711625.
245. Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K., and Sanudo-Pena, M.C. 1999. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U.S.A. 96(21): 12198–12203. doi:10.1073/pnas.96.21.12198. PMID:10518599.
246. Wang, P.F., Jiang, L.S., Bu, J., Huang, X.J., Song, W., Du, Y.P., et al. 2012. Cannabinoid-2 receptor activation protects against infarct and ischemiareperfusion heart injury. J. Cardiovasc. Pharmacol. 59(4): 301–307. doi:10.1097/FJC.0b013e3182418997. PMID:22113346.
247. Watanabe, S., Doshi, M., and Hamazaki, T. 2003. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot. Essent. Fatty Acids, 69(1): 51–59. doi:10.1016/S0952-3278(03)00056-5. PMID:12878451.
248. Wei, B.Q., Mikkelsen, T.S., McKinney, M.K., Lander, E.S., and Cravatt, B.F. 2006. A second fatty acidamidehydrolase with variable distributionamongplacentalmammals. J. Biol. Chem. 281(48): 36569–36578. doi:10.1074/jbc.M606646200. PMID: 17015445.
249. Weis, F., Beiras-Fernandez, A., Sodian, R., Kaczmarek, I., Reichart, B., Beiras, A., et al. 2010. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J. Mol. Cell. Cardiol. 48(6): 1187–1193. doi:10.1016/j.yjmcc.2009.10.025. PMID:19931541.
250. Wood, J.T., Williams, J.S., Pandarinathan, L., Janero, D.R., Lammi-Keefe, C.J., and Makriyannis, A. 2010. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J. Lipid Res. 51(6): 1416–1423. doi:10.1194/jlr.M002436. PMID:20071693.
251. Wright, K., Rooney, N., Feeney, M., Tate, J., Robertson, D., Welham, M., et al. 2005. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 129(2): 437–453. doi:10.1016/j.gastro.2005.05.026. PMID:16083701.
252. Yang, H., Zhou, J., and Lehmann, C. 2016. GPR55 – a putative “type 3” cannabinoid receptor in inflammation. J. Basic Clin. Physiol. Pharmacol. 27(3): 297–302. doi:10.1515/jbcpp-2015-0080. PMID:26669245.
253. Zaccagnino, P., Corcelli, A., Baronio, M., and Lorusso, M. 2011. Anandamide inhibits oxidative phosphorylation in isolated liver mitochondria. FEBS Lett. 585(2): 429–434. doi:10.1016/j.febslet.2010.12.032. PMID:21187088.
254. Zajicek, J., Ball, S., Wright, D., Vickery, J., Nunn, A., Miller, D., et al. 2013. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 12(9): 857–865. doi:10.1016/S1474-4422(13)70159-5. PMID:23856559.
255. Zhao, Y., Liu, Y., Zhang, W., Xue, J., Wu, Y.Z., Xu, W., et al. 2010a. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur. J. Pharmacol. 649(1–3): 285–292. doi:10.1016/j.ejphar.2010.09.027. PMID:20868672.
256. Zhao, Y., Yuan, Z., Liu, Y., Xue, J., Tian, Y., Liu, W., et al. 2010b. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J. Cardiovasc. Pharmacol. 55(3): 292–298. doi:10.1097/FJC.0b013e3181d2644d. PMID:20075743.
257. Zheng, X., Sun, T., and Wang, X. 2013. Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1alpha pathway. Biochem. Biophys. Res. Commun. 436(3): 377–381. doi:10.1016/j.bbrc.2013.05.108. PMID:23747418.
258. Zuurman, L., Ippel, A.E., Moin, E., and van Gerven, J.M. 2009. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br. J. Clin. Pharmacol. 67(1): 5–21. doi:10.1111/j.1365-2125.2008.03329.x. PMID:19133057.
259. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sorgard, M., Di Marzo, V., et al. 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400(6743): 452–457. doi:10.1038/22761. PMID:10440374.